From Susceptibility to Disease Severity: Re-Discovering the Clinical Role of MMP-12 Genotypes in Asthma
Life · 22.07.2026 · 16 (7) · 1211
DOI: 10.3390/life16071211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 22.07.2026. Verfasst von Shou-Cheng Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Taichung Armed Forces General Hospital, Taichung 411228, Taiwan. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taichung Armed Forces General Hospital, China Medical University and Asia University.
Abstract (Originalsprache)
Asthma is a chronic inflammatory airway disorder influenced by genetic and environmental factors. Matrix metalloproteinase-12 (MMP-12) plays a key role in airway remodeling and inflammation, but its genetic contribution to asthma remains unclear. This study investigated the associations of MMP-12 rs2276109 and rs652438 polymorphisms with asthma susceptibility and severity in 198 Taiwanese asthma patients and 453 controls. Genotypes were determined by PCR-RFLP, and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using logistic regression. Neither MMP-12 rs2276109 nor rs652438 was significantly associated with overall asthma susceptibility. For rs2276109, the CT and CC genotypes yielded ORs of 1.06 (95% CI = 0.56–2.00, p = 0.9913) and 6.98 (95% CI = 0.72–67.59, p = 0.0857), respectively. However, among individuals aged 25–40 years, rs652438 CT and CC genotypes were associated with elevated asthma risk (OR = 1.86, 95% CI = 1.14–3.04, p = 0.0100; OR = 3.60, 95% CI = 1.11–11.65, p = 0.0494). Furthermore, MMP-12 rs652438 was significantly associated with asthma severity under both the CT genotype (OR = 2.32, 95% CI = 1.16–4.62, p = 0.0250) and dominant models (OR = 2.45, 95% CI = 1.28–4.72, p = 0.0106). Although MMP-12 polymorphisms do not appear to influence overall asthma susceptibility, rs652438 may serve as a genetic marker for disease severity and clinical stratification in asthma.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Taichung Armed Forces General Hospital, Taichung 411228, Taiwan.
- Department of Medical Planning, Medical Affairs Bureau, Ministry of National Defense, Taipei 104237, Taiwan.
- National Defense Medical University, Taipei 114201, Taiwan.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung 404327, Taiwan.
- Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung 404327, Taiwan.
- School of Medicine, College of Medicine, China Medical University, Taichung 404333, Taiwan.
ORCID-Profile: Jie-Long He, Da-Tian Bau
Förderung
- Taichung Armed Forces General Hospital
- China Medical University and Asia University
Zitieren
APA
Wang, S. C., Hsia, T. C., Shen, T. C., Hang, L. W., He, J. L., Chen, D. H., Huang, K. L., Tsai, C. W., Chang, W. S., & Bau, D. T. (2026). From Susceptibility to Disease Severity: Re-Discovering the Clinical Role of MMP-12 Genotypes in Asthma. Life, 16(7), 1211. https://doi.org/10.3390/life16071211
Vancouver
Wang SC, Hsia TC, Shen TC, Hang LW, He JL, Chen DH, et al. From Susceptibility to Disease Severity: Re-Discovering the Clinical Role of MMP-12 Genotypes in Asthma. Life. 2026;16(7):1211. doi:10.3390/life16071211
BibTeX
@article{Wang2026,
author = {Wang, Shou-Cheng and Hsia, Te-Chun and Shen, Te-Chun and Hang, Liang-Wen and He, Jie-Long and Chen, Ding-Han and Huang, Kai-Ling and Tsai, Chia-Wen and Chang, Wen-Shin and Bau, Da-Tian},
title = {From Susceptibility to Disease Severity: Re-Discovering the Clinical Role of MMP-12 Genotypes in Asthma},
journal = {Life},
year = {2026},
volume = {16},
number = {7},
pages = {1211},
doi = {10.3390/life16071211}
}
EUVIMED